A 3-year-old girl from Delhi presents with bilateral leukocoria and strabismus. Her father reports that the right eye has been turning inward for the past 4 months. Dilated fundoscopy reveals a creamy-white mass in the superotemporal quadrant of the right eye and a smaller lesion in the nasal periphery of the left eye. B-scan ultrasound confirms intraocular calcification in both eyes. Genetic testing reveals a heterozygous RB1 mutation. The right eye lesion is classified as Group D (IIRC) and the left eye as Group B. What is the most appropriate management strategy for this child?

Explanation

## Clinical Context: Bilateral Retinoblastoma with Hereditary Mutation This is a **hereditary bilateral retinoblastoma** (RB1 mutation-positive) with asymmetric disease: - **Right eye:** Group D (advanced intraocular disease, high risk of treatment failure) - **Left eye:** Group B (intermediate risk, good prognosis with chemotherapy + focal therapy) ## Key Principle in Bilateral RB **High-Yield:** In bilateral RB, the goal is to **preserve both globes whenever possible** using systemic chemotherapy as the backbone. Each eye is treated according to its classification, but the chemotherapy is systemic (benefits both eyes) and focal therapy is tailored to each eye's response. **Key Point:** Enucleation is reserved as a salvage procedure for eyes that fail chemotherapy or develop Group E features (phthisical eye, neovascular glaucoma, extraocular extension). ## Management Algorithm for Bilateral RB ```mermaid flowchart TD A[Bilateral Retinoblastoma]:::outcome --> B[Systemic Chemotherapy<br/>Both Eyes]:::action B --> C{Assess Response<br/>at 4-6 weeks}:::decision C -->|Right Eye: Good| D[Focal Therapy:<br/>Laser/Cryo/Brachy]:::action C -->|Right Eye: Poor| E[Enucleation Right]:::urgent C -->|Left Eye: Good| F[Focal Therapy:<br/>Laser/Cryo/Brachy]:::action C -->|Left Eye: Poor| G[Consider Enucleation Left]:::urgent D --> H[Serial Surveillance<br/>Both Eyes]:::action E --> H F --> H ``` ## Why Systemic Chemotherapy for Both Eyes? | Reason | Explanation | |--------|-------------| | **Bilateral disease** | Systemic chemo reaches both eyes via circulation | | **Hereditary mutation** | Higher risk of bilateral involvement; chemo is preventive for subclinical disease | | **Preserves globes** | Allows time for focal therapy response; enucleation deferred | | **Better outcomes** | 70–90% globe salvage in Groups A–D with chemo + focal therapy | **Clinical Pearl:** In bilateral RB, even if one eye is Group D (worse prognosis), systemic chemotherapy is still initiated. The Group D eye may still respond and avoid enucleation; if not, enucleation is performed after chemotherapy failure is documented. ## Hereditary RB: Special Considerations **Mnemonic: HEREDITARY RB RISKS** — **H**igher bilateral risk, **E**arly presentation, **R**B1 germline mutation, **E**nhanced surveillance needed, **D**ifferent treatment paradigm, **I**ncreased secondary malignancy risk, **T**arget both eyes, **A**void EBRT (secondary cancers), **R**egular genetic counselling, **Y** — Yes, systemic chemo is standard. 1. **Germline RB1 mutation** → 90% risk of bilateral disease if untreated 2. **Secondary malignancies:** EBRT increases risk to 50% by age 50 → avoided in hereditary RB 3. **Systemic chemotherapy** is preferred over radiotherapy 4. **Genetic counselling** for family members ## Why NOT Immediate Enucleation of Right Eye? - **Group D is not Group E:** Group D disease can respond to chemotherapy in 30–50% of cases - **Hereditary mutation:** Preserving one eye is critical; bilateral enucleation would render the child blind - **Modern evidence:** Chemotherapy-first approach has improved outcomes even for Group D eyes - **Enucleation is salvage:** Reserved for chemotherapy failure, not primary treatment ## Why NOT EBRT? **Warning:** External beam radiotherapy is contraindicated in hereditary RB because: - Secondary malignancy risk rises to 50% by age 50 (vs. 5–10% with chemotherapy) - Chemotherapy achieves comparable globe salvage without this risk - Modern chemotherapy regimens are highly effective ## Expected Treatment Course 1. **Weeks 0–12:** Systemic chemotherapy (carboplatin + etoposide ± vincristine) × 4–6 cycles 2. **Weeks 4–6:** First response assessment - Right eye: If responding → focal therapy; if not → enucleation - Left eye: If responding → focal therapy; if not → consider enucleation 3. **Months 3–24:** Serial dilated fundoscopy and imaging every 4–6 weeks 4. **Years 2–5:** Surveillance every 3 months; then annual lifelong **Clinical Pearl:** The left eye (Group B) has an excellent prognosis (~90% globe salvage with chemo + focal therapy). The right eye (Group D) is higher risk but still warrants a chemotherapy trial before enucleation. [cite:Boyd & Murphree, Retinoblastoma, in Ophthalmology 4e Ch 12; COG (Children's Oncology Group) Retinoblastoma Protocol]